LifeSci Capital Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)

LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Tenaya Therapeutics (TNYAResearch Report) today and set a price target of $16.00. The company’s shares opened today at $3.15.

According to TipRanks, Dolezal is a 3-star analyst with an average return of 1.3% and a 33.82% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Tenaya Therapeutics, and Celldex.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tenaya Therapeutics with a $15.67 average price target, representing a 397.46% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.

See today’s best-performing stocks on TipRanks >>

TNYA market cap is currently $229.7M and has a P/E ratio of -1.19.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNYA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.

Read More on TNYA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More